Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.47 |
| ▸ | RPS6KA5 | O75582 | 2/20 | 0.41 |
| ▸ | AKT1 | P31749 | 2/20 | 0.41 |
| ▸ | GSK3B | P49841 | 2/20 | 0.41 |
| ▸ | NEK4 | P51957 | 2/20 | 0.41 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.41 |
| ▸ | PRKG2 | Q13237 | 2/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.41 |
| ▸ | PRKG1 | Q13976 | 2/20 | 0.41 |
| ▸ | PKN2 | Q16513 | 2/20 | 0.41 |
| ▸ | CLK4 | Q9HAZ1 | 2/20 | 0.41 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.41 |
| ▸ | DYRK3 | O43781 | 1/20 | 0.41 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.41 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.41 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.41 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.41 |
| ▸ | PRKCG | P05129 | 1/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1109400 | 0.82 | CTSB (0.47) | RPS6KA5AKT1GSK3BNEK4PRKCD | |
| SCHEMBL27543249 | 0.80 | HDAC1 (0.58) | ROCK1ROCK2HDAC1HDAC6HDAC3 | |
| SCHEMBL7471460 | 0.80 | HDAC1 (0.58) | ROCK1ROCK2HDAC1HDAC6HDAC3 | |
| SCHEMBL404192 | 0.80 | GRM5 (0.38) | — | |
| SCHEMBL1109525 | 0.79 | HDAC1 (0.42) | RPS6KA5AKT1GSK3BNEK4PRKCD | |
| SCHEMBL1912214 | 0.79 | HDAC4 (0.47) | HDAC4RPS6KA5AKT1GSK3BPRKCD | |
| SCHEMBL405427 | 0.78 | — | — | |
| SCHEMBL401005 | 0.78 | HPGDS (0.54) | HDAC4RPS6KA5AKT1GSK3BNEK4 | |
| SCHEMBL401441 | 0.78 | HPGDS (0.54) | HDAC4RPS6KA5AKT1GSK3BNEK4 | |
| SCHEMBL27873381 | 0.78 | KDM4E (0.53) | HDAC4PIM1MAOAHDAC1HDAC3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153843-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2012-04-10 | — | — | US | disclosed |
| US-8101640-B2 | Antibacterial agents | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2012-01-24 | — | — | US | disclosed |
| US-8084615-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2011-12-27 | — | — | US | disclosed |
| US-7989660-B2 | BACTERICIDE AGAINST GRAMNEGATIVE BACTERIA; RESPIARATORY SYSTEM DISORDERS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. (US) | 2011-08-02 | — | — | US | disclosed |
| US-20110172174-A1 | Antibacterial agents | NOVARTIS VACCINES AND DIAGNOSTICS INC. | 2011-07-14 | — | — | US | disclosed |
| US-20100324025-A1 | Antibacterial Agents | UNIVERSITY OF WASHINGTON (US) | 2010-12-23 | — | — | US | disclosed |
| US-20090247506-A1 | Antibacterial agents | CHIRON CORPORATION | 2009-10-01 | — | — | US | disclosed |
| US-20090163496-A1 | ANTIBACTERIAL AGENTS | UNIVERSITY OF WASHINGTON (US) | 2009-06-25 | — | — | US | disclosed |
| US-20080269221-A1 | ANTIBACTERIAL AGENTS | NOVARTIS VACCINES AND DIAGNOSTICS, INC. | 2008-10-30 | — | — | US | disclosed |
| US-7358359-B2 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2008-04-15 | — | — | US | disclosed |
| US-20070244197-A1 | Antibacterial agents | UNIVERSITY OF WASHINGTON (US) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070244197-A1 | Antibacterial agents | MRPL21, SI, PGLS | HDAC4 1820/4885RPS6KA5 332/4885AKT1 1292/4885 |
| US-20090247506-A1 | Antibacterial agents | MRPL21, SI, PGLS | HDAC4 1820/4885RPS6KA5 332/4885AKT1 1292/4885 |
| US-20110172174-A1 | Antibacterial agents | MRPL21, SI, PGLS | HDAC4 1820/4885RPS6KA5 332/4885AKT1 1292/4885 |
| US-20080269221-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, PGLS | HDAC4 1820/4885RPS6KA5 332/4885AKT1 1292/4885 |
| US-20090163496-A1 | ANTIBACTERIAL AGENTS | MRPL21, SI, PGLS | HDAC4 1820/4885RPS6KA5 332/4885AKT1 1292/4885 |
| US-20100324025-A1 | Antibacterial Agents | MRPL21, SI, PGLS | HDAC4 1820/4885RPS6KA5 332/4885AKT1 1292/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.